Lataa...
What have we learnt from Vioxx?
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group Ltd.
2007
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1779871/ https://ncbi.nlm.nih.gov/pubmed/17235089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmj.39024.487720.68 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|